Clinical Trial Update: Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of two formulations of GSK's human rotavirus vaccine in healthy infants; study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infections
• Rotavirus Vaccines-related Disease

Drugs mentioned

• HRV vaccine (human rotavirus vaccine) 444563 (human rotavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus, Rotavirus Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2019-10-14